2021 年第 10 期 第 16 卷

瑞舒伐他汀钙片联合依折麦布片对冠心病合并高脂蛋白血症患者血清生化指标和临床症状的影响

Effects of rosuvastatin calcium tablets combined with ezetimibe tablets on serum biochemical indexes and clinical symptoms in patients with coronary atherosclerotic heart disease complicated with hyperlipoproteinemia

作者：寻玉君1董芳2

英文作者：Xun Yujun1 Dong Fang2

单位：1山东省滕州市中医医院药学部277599；2山东省滕州市中医医院心内科277599

英文单位：1Department of Pharmacy Tengzhou Traditional Chinese Medical Hospital Shandong Province Tengzhou 277599 China; 2Department of Cardiology Tengzhou Traditional Chinese Medical Hospital Shandong Province Tengzhou 277599 China

关键词：冠心病（冠状动脉粥样硬化性心脏病）；瑞舒伐他汀钙片；依折麦布片；血脂；炎症因子

英文关键词：Coronaryatheroscleroticheartdisease;Rosuvastatincalciumtablets;Ezetimibetablets;Bloodlipid;Inflammatoryfactors

• 摘要：

• 目的  探讨瑞舒伐他汀钙片联合依折麦布片对冠心病（冠状动脉粥样硬化性心脏病）合并高脂蛋白血症（HLP）患者血清生化指标和临床症状的影响。方法 回顾性分析2017年1月至2019年8月山东省滕州市中医医院收治的120例冠心病合并HLP患者的临床资料，根据治疗方式分为观察组和对照组，各60例。对照组予瑞舒伐他汀钙片口服治疗，观察组在对照组基础上联合依折麦布片口服治疗，均连续治疗12周。比较2组临床疗效、治疗前后血脂及炎症因子指标，记录治疗期间不良反应发生情况。结果 治疗后，观察组总有效率高于对照组，差异有统计学意义（P=0.041）。2组治疗后血清总胆固醇、三酰甘油、低密度脂蛋白胆固醇水平均低于治疗前，且观察组均低于对照组［（4.1±0.9）mmol/L比（4.9±1.0）mmol/L、（1.6±0.3）mmol/L比（1.8±0.6）mmol/L、（2.6±0.4）mmol/L比（3.1±0.5）mmol/L］，2组高密度脂蛋白胆固醇水平均高于治疗前，且观察组高于对照组［（1.56±0.37）mmol/L比（1.22±0.43）mmol/L］，差异均有统计学意义（均P＜0.05）。治疗后，2组肿瘤坏死因子α、高敏C反应蛋白、白细胞介素6水平均低于治疗前，且观察组均低于对照组（均P＜0.001）。治疗后2组心绞痛、心慌胸闷、气短、乏力症状积分均低于治疗前，且观察组均低于对照组，差异均有统计学意义（均P＜0.001）。治疗期间2组不良反应发生率差异无统计学意义（P＞0.05）。结论 相比于单纯使用瑞舒伐他汀钙片，瑞舒伐他汀钙片联合依折麦布片治疗冠心病合并HLP患者可明显减轻机体炎症反应，调节血脂水平，改善心绞痛等临床症状，改善患者生活质量。

• Objective To explore effects of rosuvastatin calcium tablets combined with ezetimibe tablets on serum biochemical indexes and clinical symptoms in patients with coronary atherosclerotic heart disease(CHD) complicated with  hyperlipoproteinemia(HLP). Methods From January 2017 to August 2019, clinical data of 120 patients with CHD complicated with HLP admitted to Tengzhou Traditional Chinese Medical Hospital, Shandong Province were retrospectively analyzed. They were randomly divided into observation group and control group, with 60 cases in each group. The control group was treated with rosuvastatin calcium tablets orally, and the observation group was treated with ezetimibe tablets orally based on the control group. Both groups were treated for 12 weeks. The clinical effect, and blood lipid and inflammatory factors before and after treatment were compared between the two groups. Adverse reactions were recorded during the treatment. Results After treatment, total effective rate in observation group was higher than that in control group(P=0.041). After treatment, the serum levels of total cholesterol, triglyceride, low-density lipoprotein cholesterol in both groups were lower than those before treatment, and those in observation group were lower than those in control group［（4.1±0.9）mmol/L vs （4.9±1.0）mmol/L, （1.6±0.3）mmol/L vs （1.8±0.6）mmol/L, （2.6±0.4）mmol/L vs （3.1±0.5）mmol/L］; after treatment, the levels of high-density lipoprotein cholesterol in both groups were higher than those before treatment, and that in observation group was higher than that in control group［（1.56±0.37）mmol/L vs （1.22±0.43）mmol/L］(all P<0.05). After treatment, the levels of tumor necrosis factor-α, high-sensitivity C-reactive protein and interleukin-6 in both groups were lower than those before treatment, and those in observation group were lower than those in control group(all P<0.001). After treatment, the scores of angina, palpitation and chest distress, shortness of breath and fatigue in both groups were lower than those before treatment, and those in observation group were lower than those in control group(all P<0.001). There was no significant difference in the incidence of adverse reactions during treatment between the two groups(P>0.05). Conclusion Comparing with rosuvastatin calcium tablets alone, rosuvastatin calcium tablets combined with ezetimibe tablets in treatment of patients with CHD complicated with HLP can significantly alleviate inflammatory response, regulate blood lipid level, improve clinical symptoms such as angina, and improve quality of patients′ lives.